Rush for Generic Go-Ahead on Novel Drugs Roils Pharma Industry

As generic drug makers compete for first-filer status of generic versions of branded products, the pharmaceutical industry has seen an increase in litigation from brand-name drug makers to defend their patents from multiple companies for a single drug. In addition to increased pressure for transparency over drug prices, there are concerns over whether the current system is beneficial for drug makers and consumers. Bloomberg Law contacted Finnegan partner Scott Burwell for his thoughts.

Scott commented on the impact the trend of increased first-filers is having on litigation. He said, “It does increase the complexity and the cost of litigation because the innovators now have multiple fronts on which to fight.”

Read the full article here.